RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals today announced the awarding of a $1.95 million grant from the Department of Defense, Defense Medical Research and Development Program, focused on the development of a novel topical antifungal agent to prevent and treat mold infections as a result of battlefield wounds. This Military Infectious Diseases Applied Research Award began funding in April and will fund research and development activities over a three year period.
Viamet is currently advancing a broad portfolio of novel antifungal agents based upon its proprietary Metallophile Technology ® platform. All compounds in the Viamet antifungal portfolio are highly potent and were specifically designed to avoid the safety and pharmacokinetic issues that limit currently marketed antifungal agents. To date, the Company has focused its development activities on compounds that are administered either orally or intravenously. However, certain compounds are also appropriate for topical administration, including the potential to prevent and treat mold infections of battlefield wounds.
“We are pleased to announce the receipt of this grant from the Department of Defense,” remarked Robert Schotzinger, MD, PhD, CEO of Viamet. “We believe that Viamet has the broadest and most robust portfolio of novel antifungal agents in the industry today. We look forward to extending the application of our novel compounds to include the prevention and treatment of mold infections resulting from battlefield wounds that occur in our US military personnel.”
About Viamet (www.viamet.com)
Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on a proprietary metalloenzyme medicinal chemistry platform, the Metallophile Technology ®. The Company is using this platform to design drugs that are expected to have greater selectivity and safety as well as improved potency compared to currently available therapeutics. The Company’s initial product candidates include a portfolio of highly potent and selective novel antifungal agents.
This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet’s business and VT-1161, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.
